Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2)

Genes Chromosomes and Cancer

Volumn 48, Issue 2, 2009, Pages 179-183

  Walz, Christoph ^a   Haferlach, Claudia ^b   Hänel, Annette ^c   Metzgeroth, Georgia ^a   Erben, Philipp ^a   Gosenca, Darko ^a   Hochhaus, Andreas ^a   Cross, Nicholas C P ^d   Reiter, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Münchner Leukämie Labor   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; BLOOD EXAMINATION; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BAND; DISEASE ASSOCIATION; EOSINOPHILIA; FUSION GENE; GENE IDENTIFICATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; INVERSE POLYMERASE CHAIN REACTION; MALE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHROMOSOME PAINTING; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 5; EOSINOPHILIA; GENE FUSION; HUMANS; MALE; MIDDLE AGED; MUTANT CHIMERIC PROTEINS; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; MYOSINS; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSLOCATION, GENETIC;

EID: 59949103230     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20629     Document Type: Article

References (20)

1. Bastie JN, Garcia I, Terre C, Cross NC, Mahon FX, Castaigne S. 2004. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor β-gene. Haematologica 89:1263-1264.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145.
3. Chen J, Williams IR, Kutok JL, Duclos N, Anastasiadou E, Masters SC, Fu H, Gilliland DG. 2004. Positive and negative regulatory roles of the WW-like domain in TEL-PDGFßR transformation. Blood 104:535-542.
4. Cross M, Csar XF, Wilson NJ, Manes G, Addona TA, Marks DC, Whitty GA, Ashman K, Hamilton JA. 2004. A novel 110 kDa form of myosin XVIIIA (MysPDZ) is tyrosine-phosphorylated after colony-stimulating factor-1 receptor signalling. Biochem J 380:243-253.
5. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, McArthur GA, Mahon FX, Massimini G, Melo J, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, Stark A, Waghorn K, Nikolova Z, Apperley JF. 2007. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109:61-64.
6. Furusawa T, Ikawa S, Yanai N, Obinata M. 2000. Isolation of a novel PDZ-containing myosin from hematopoietic supportive bone marrow stromal cell lines. Biochem Biophys Res Commun 270:67-75.
7. Grand FH, Burgstaller S, Kuhr T, Baxter EJ, Webersinke G, Thaler J, Chase AJ, Cross NC. 2004. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 64:7216-7219.
8. Gunby RH, Cazzaniga G, Tassi E, le Coutre P, Pogliani E, Specchia G, Biondi A, Gambacorti-Passerini C. 2003. Sensitivity to imatinib but low frequency of the TEL/PDGFR beta fusion protein in chronic myelomonocytic leukemia. Haematologica 88:408-415.
9. Irusta PM, Luo Y, Bakht O, Lai CC, Smith SO, DiMaio D. 2002. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J Biol Chem 277:38627-38634.
10. Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
11. Lupas A, Van Dyke M, Stock J. 1991. Predicting coiled coils from protein sequences. Science 252:1162-1164.
12. Mori K, Furusawa T, Okubo T, Inoue T, Ikawa S, Yanai N, Mori KJ, Obinata M. 2003. Genome structure and differential expression of two isoforms of a novel PDZ-containing myosin (MysPDZ)(Myo18A). JBiochem(Tokyo)133:405-413.
13. Reiter A, Walz C, Cross NCP. 2007. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 8:205-216.
14. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. 2002. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99:10700-10705.
15. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, Williams IR, Gilliland DG, Cools J. 2006. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 103:8078-8083.
16. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. 2007. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097.
17. Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, Fuchs R, Schmitt-Graff A, Hehlmann R, Cross NC, Reiter A. 2005. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndromefusesMYO18AtoFGFR1.Leukemia19:1005-1009.
18. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graff A, Fabarius A, Haferlach T, Hagen V, Lathan B, Prummer O, Rauh S, Hehlmann R, Hochhaus A, Cross NCP, Reiter A. 2007. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 91:163-169.
19. Walz C, Cross NC, Van Etten RA, Reiter A. 2008. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22:1320-1334.
20. Yang CH, Szeliga J, Jordan J, Faske S, Sever-Chroneos Z, Dorsett B, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Whit-sett JA, Chroneos ZC. 2005. Identification of the surfactant protein A receptor 210 as the unconventional myosin 18A. J Biol Chem 280:34447-34457.